Next Article in Journal
Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets
Previous Article in Journal
Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy

by
Olivia A. Diaz Arguello
and
Hidde J. Haisma
*
Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, 9713AV Groningen, The Netherlands
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(7), 1543; https://doi.org/10.3390/cancers13071543
Submission received: 23 February 2021 / Revised: 21 March 2021 / Accepted: 25 March 2021 / Published: 27 March 2021
(This article belongs to the Section Cancer Therapy)

Simple Summary

Cancer is a complicated disease that has a significant characteristic of evading cell death (apoptosis). The induction of apoptosis in cancerous cells seems a promising procedure to use as a cancer treatment. In the family of the tumor necrosis factor (TNF) proteins, there are some ligands with the capability to induce apoptosis. Several recombinant TNF apoptosis-inducing ligands have been designed over the years, and their characteristics have been improved. This review provides an overview of the studies done in different stages of the TNF apoptosis-inducing ligands as cancer treatments and the strategies to surpass their natural limitations to improve their effectiveness.

Abstract

Cancer is a complex disease with apoptosis evasion as one of its hallmarks; therefore, apoptosis induction in transformed cells seems a promising approach as a cancer treatment. TNF apoptosis-inducing ligands, which are naturally present in the body and possess tumoricidal activity, are attractive candidates. The most studied proteins are TNF-α, FasL, and TNF-related apoptosis-inducing ligand (TRAIL). Over the years, different recombinant TNF family-derived apoptosis-inducing ligands and agonists have been designed. Their stability, specificity, and half-life have been improved because most of the TNF ligands have the disadvantages of having a short half-life and affinity to more than one receptor. Here, we review the outlook on apoptosis-inducing ligands as cancer treatments in diverse preclinical and clinical stages and summarize strategies of overcoming their natural limitations to improve their effectiveness.
Keywords: cancer; apoptosis; TNF family; death receptors cancer; apoptosis; TNF family; death receptors
Graphical Abstract

Share and Cite

MDPI and ACS Style

Diaz Arguello, O.A.; Haisma, H.J. Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy. Cancers 2021, 13, 1543. https://doi.org/10.3390/cancers13071543

AMA Style

Diaz Arguello OA, Haisma HJ. Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy. Cancers. 2021; 13(7):1543. https://doi.org/10.3390/cancers13071543

Chicago/Turabian Style

Diaz Arguello, Olivia A., and Hidde J. Haisma. 2021. "Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy" Cancers 13, no. 7: 1543. https://doi.org/10.3390/cancers13071543

APA Style

Diaz Arguello, O. A., & Haisma, H. J. (2021). Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy. Cancers, 13(7), 1543. https://doi.org/10.3390/cancers13071543

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop